Cipargamin is an antimalarial drug candidate, under clinical development. It is the optimised lead for the spiroindolones, a novel class of compounds identified from a phenotypic screen as having antimalarial activity [3
] and awarded MMV Project of the Year (2009)
The active enantiomer is shown here, with the 1R,3S configuration essential for antimalarial activity [3
tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.